Ms. Chen has over 13 years of professional experience in the nutraceutical industry and is an expert in production of capsules, tablets (plain, chewable, film coated, enteric coated, time-releasing coated), granules, powder extracts and liquid extracts, soft gels, and tincture for conformance to specifications in accordance with USP, SOPs and GMP standards. Moreover, she is involved with technical management, supervision and control of industrial production processes. By combining both science knowledge and business concepts, she makes sure all manufacturing processes run smoothly and cost-effectively, and deliver high quality products to clients on time.
Chen, et al. (2011), “Simultaneous quantification of polyherbal formulations containing Rhodiola rosea L. and Eleutherococcus senticosus Maxim. using rapid resolution liquid chromatography (RRLC)”, Journal of Pharmaceutical and Biomedical Analysis, 55, PP.908-915.
Dr. Lin obtained his medical education in Guangdong Medical University, China and fellowship training in endocrinology, metabolism and nutrition in University of Washington, USA. He completed his Ph.D. in Biochemistry, McGill University, Canada. He served as a physician and researcher in numerous institutions. His main contributions include theory of high density lipoprotein A-1(apoA-1) receptor-mediated cholesterol exocytosis pathway to prevent atherosclerotic heart disease, enzyme phosphorylation to regulate Krebs cycle and high energy metabolism, and superoxide (ROS stress) production through enzymatic phosphorylation of the complex I subunit in ETC chains. He also played a leading role in identification of PDE4 inhibitor as potential agent to treat low HDL cholesterol, ROCK inhibitor for diabetic myocardiopathy and methyl protodioscin as a transcriptional inhibitor to treat combined dyslipidemia. He joined the company in late 2016 in prospective to new product development, education and awareness of health benefits of natural products to clients.
Lin et al. (2015). “Methyl protodioscin increases ABCA1 expression and cholesterol efflux while inhibiting gene expressions for synthesis of cholesterol and triglycerides by suppressing SREBP transcription and microRNA 33a/b levels.” Atherosclerosis. 239(2):566-70.
Review on “Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats” by Stephan L.M. Peters & Martin C. Michel (2007), Cardiovascular Research ( 7), pp. 3-4.
Dr. Peudru’s research work focuses on chemical synthesis of novel chemical compounds and their potential applications at the insitution. Dr. Peudru then served as teaching professional in Organic Chemistry (Synthesis and Analysis) & Biochemistry at the University, and Technical Institute of Caen biological engineering department. She moved from France to Canada to combine her knowledge in chemistry and her passion for the natural healing power to start her carrier in the natural health product industry. She is an expert on Canadian health product regulation for the natural product number (NPN) applications. Under her leadership, the company obtains over 700 natural product licenses from the Health Canada, and is the top licensee in phytopharmaceutical industry of Canada.
Peudru et al. (2016),”Synthesis of 1,3-thiazines by a three-component reaction and their transformations into β- lactam-condensed 1,3-thiazine and 1,4-thiazepine derivatives, Phosphorus, Sulfur, and Silicon and the Related Elements”, Tandfonline 191:2, pp. 220-229.
Dr. Singjunla received his education from France, with BSc in Industrial Chemistry at the University of Bordeaux 1, Master of Science from the University of Lyon1 Claude Bernard, Doctor of Philosophy and Post Doctor training from the University of Caen Basse-Normandie. His expertise is in properties of non-proteinogenic amino acids and its application. The non-proteinogenic amino acids are natural or synthetic compounds that not naturally encoded or found in the genetic code of proteins in any organism. These amino acids may possess physiological activity and pharmacological applications. He joins the company in 2017 as an QC/ R&D Scientist to apply his knowledge in developing natural health products.
Mr. Wang is a scholar, scientist and corporate executive with nearly 30-year experience in phytomedicine and phytopharmaceutical industry. He later served as a research scientist, an associate professor and a vice director of the natural product chemistry laboratory of the Beijing university of Chinese Medicine. After arriving Canada in 2001, Mr. Wang served as a research scientist for a biomedical company and several NHP companies. Mr. Wang joined Canadian Phytopharmaceuticals Corp. as QC Manager in 2004 and became head of R&D shortly after. During this period, Mr. Wang successfully managed more than 100 contract research projects (CRPs) and contract manufacture projects (CMPs). He has over 30 scientific publications, some of them in respected journals.
Wang et al. (2011), “Simultaneous Quantification of Echinacea Species, Flos Lonicerae, Radix Scutellaria and Fructus Forsythiae Combinations by Rapid Resolution Liquid Chromatography”, Natural Product Communications, 6:5, pp. 639-643.
(2011), “Rapid resolution liquid chromatorgraphy (RRLC) analysis and studies on the stability of Shuang-Huang-Lian preparations,” Journal of Pharmaceutical and Biomedical Analysis, 54, pp. 265-272.
(2011), “Simultaneous quantification of polyherbal formulations containing Rhodiola rosea L. and Eleutherococcus senticosus Maxim using rapid resolution liquid chromatography (RRLC),” Journal of Pharmaceutical and Biomedical Analysis, 55, pp. 908-915.
(2011), “Simultaneous quantification of Panax and Epimedium species using rapid resolution liquid chromatography (RRLC),” Natural Product Communications, 6, pp. 581-586.
(2011), “Rapid Resolution Liquid Chromatography (RRLC) Analysis for Quality Control of Rhodiola rosea Roots and Commercial Standardized Products”, Natural Product Communications, 6:5, pp. 645-650.
(2011), ” Rapid resolution liquid chromatography (RRLC) analysis and studies on the stability of Shuang-Huang-Lian preparations “, Journal of Pharmaceutical and Biomedical Analysis, 54, pp. 265-272.